Učitavanje...
Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension
BACKGROUND: Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, b...
Spremljeno u:
| Izdano u: | Cardiovasc Diagn Ther |
|---|---|
| Glavni autori: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7666951/ https://ncbi.nlm.nih.gov/pubmed/33224780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/cdt.2020.04.01 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|